EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A framework for outpatient CAR-T monitoring to support Canadian CAR-T capacity building

Amaris Balitsky, Christopher Lemieux

Canadian Hematology Today · 24.11.2026 · 2-11

DOI: 10.58931/cht.2026.5s0495 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Canadian Hematology Today, online erschienen am 24.11.2026. Verfasst von Amaris Balitsky und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction: why outpatient CAR-T therapy now in Canada? Chimeric antigen receptor T cell (CAR-T) therapy has significantly improved outcomes, including sustained remissions and even cures, for patients with refractory or relapsed B-cell non-Hodgkin lymphoma (NHL), B-cell acute lymphoblastic leukemia (ALL), and multiple myeloma (MM).1-8 CAR-T products differ by antigen target, such as CD19 and B cell maturation antigen (BCMA); and by co-stimulatory domain, which is either CD28 (e.g., axicabtagene ciloleucel, brexucabtagene autoleucel) or 4-1BB (e.g., tisagenlecleucel, lisocabtagene maraleucel, idecabtagene vicleucel). Prior to CAR-T availability, patients with relapsed hematologic malignancies experienced poor outcomes. For example, in patients with relapsed/refractory large B-cell lymphomas, the median overall survival was 6.2 months. prior to access to CAR-T therapy.9 These outcomes are balanced by CAR-T therapy-associated toxicities, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Despite the substantial clinical benefits observed with CAR T-cell therapy, treatment is associated with distinct immune-mediated toxicities, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity (ICANs). Although these adverse events are generally manageable with established treatment algorithms and are often reversible, severe toxicities, resulting in organ dysfunction and occasionally death, may occur and can necessitate ICU-level care. Enhanced understanding of toxicity kinetics, earlier intervention strategies, and the availability of effective management approaches such as tocilizumab and corticosteroids have improved the safety profile of CAR T-cell therapy. Early interventions, such as tocilizumab (anti-IL-6R) and corticosteroids, can attenuate the severity of these toxicities. Given the potential for severe toxicities, CAR-T has traditionally been administered and monitored in an inpatient hospital setting.

Zitieren

APA

Balitsky, A., & Lemieux, C. (2026). A framework for outpatient CAR-T monitoring to support Canadian CAR-T capacity building. Canadian Hematology Today, 2-11. https://doi.org/10.58931/cht.2026.5s0495

Vancouver

Balitsky A, Lemieux C. A framework for outpatient CAR-T monitoring to support Canadian CAR-T capacity building. Canadian Hematology Today. 2026:2-11. doi:10.58931/cht.2026.5s0495

BibTeX
@article{Balitsky2026,
  author = {Balitsky, Amaris and Lemieux, Christopher},
  title = {A framework for outpatient CAR-T monitoring to support Canadian CAR-T capacity building},
  journal = {Canadian Hematology Today},
  year = {2026},
  pages = {2--11},
  doi = {10.58931/cht.2026.5s0495}
}
Kostenlos starten →